XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2019 $ 1,160   $ 4 $ 426,426 $ (425,270)
Balance (in shares) at Dec. 31, 2019   1,959 3,880,588    
Share-based compensation 247     247  
Issuance of common stock, net of offering costs 3,882   $ 2 3,880  
Issuance of common stock, net of offering costs (share)     2,150,113    
Issuance of common stock for exercise of warrants 1,098   $ 1 1,097  
Issuance of common stock for exercise of warrants (in shares)     487,521    
Reclassification of warrant liabilities 4,504     4,504  
Issuance of common stock for in process research and development acquired from NanoTx Therapeutics 381     381  
Issuance of common stock for in process research and development acquired (in share)     230,769    
Conversion of convertible preferred stock into common stock (share)   (5) 37    
Net loss (8,241)       (8,241)
Balance at Dec. 31, 2020 3,031   $ 7 436,535 (433,511)
Balance (in shares) at Dec. 31, 2020   1,954 6,749,028    
Share-based compensation 606     606  
Issuance of common stock, net of offering costs 18,581   $ 8 18,573  
Issuance of common stock, net of offering costs (share)     7,864,379    
Issuance of common stock for exercise of warrants 2,017   $ 1 2,016  
Issuance of common stock for exercise of warrants (in shares)     896,500    
Conversion of convertible preferred stock into common stock (share)   (2) 118    
Net loss (13,399)       (13,399)
Balance at Dec. 31, 2021 $ 10,836   $ 16 $ 457,730 $ (446,910)
Balance (in shares) at Dec. 31, 2021   1,952 15,510,025